FSG titles enjoy continued growth of Impact Factors
PRESS RELEASE FROM FUTURE SCIENCE GROUP
June 2010
Future Science Group titles enjoy continued growth in Impact Factors
Future Science Group (FSG) announced highlights of its latest journal Impact Factor results, with impressive results across its imprints Future Medicine and Expert Reviews, following the recent publication of the new Impact Factors in the 2009 Journal Citation Report (JCR) by Thomson Reuters. Impact Factors, calculated by Thomson Reuters indicate the number of times a published article has been cited during the course of a year – providing an indication on how much of an ‘impact’ a journals content is making on its research audience.
Together with the increase in impact factors across the Future Medicine and Expert Reviews portfolios, most journals also see an improvement in their ranking within specific categories. The star performers were Expert Review of Vaccines with an impressive increase to 4.214 from 2.979, and Future Microbiology, with an increase to 2.875 from 1.976 last year.
Launched in 2002 and 2006 respectively, Expert Review of Vaccines and Future Microbiology were selected for coverage in ISI® services and Medline at the earliest opportunity. Future Microbiology provides an interdisciplinary forum for all scientists working in the field today, bringing together the diverse subject areas of bacteriology, mycology, parasitology and virology. Expert Review of Vaccines reviews the clinical effectiveness of new vaccines, with coverage including vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines in bioterrorism.
The Editorial Advisory panel for both titles were delighted at the jump in Impact factor, Andrew J Pollard - Professor of Pediatric Infection & Immunity, Director of the Oxford Vaccine Group, University of Oxford, UK – said:
“Expert Review of Vaccines is the authoritative platform for keeping abreast of knowledge and development in the field of vaccinology – it is great news that our journal is gaining recognition and an increased readership can only make us proud.” and SH Kaufmann, Max-Planck-Institute for Infection Biology, Germany, commented:
“Future Microbiology provides cutting edge perspective on the novel concepts and technological opportunities in the fight against microbial diseases in the post-genomic era. A worthy winner, and brings with it a sense of responsibility to maintain the highest standards of scientific quality generated in our laboratories and the need to contribute to clinical practice should be the main motivating forces from now on.”
The improved 2009 Impact Factors are testament to the fact that the Future Medicine & Expert Review journals are of high quality and widely read, and highly respected by researchers. The journals are now becoming a high priority for authors wishing to submit their important research findings and scientific opinions.
Editorial Director of FSG, Elisa Manzotti said,
“….the overall trend is up, and it is fantastic to see Expert Reviews and Future Medicine titles enjoying a year on year increase. I’m also delighted to note that Expert Review of Vaccines took an impressive leap in one year, which is a huge credit to the Editorial Advisory Board and in-house team, together with the many authors and referees who are committed to the title, and made the title such an unqualified success.”
Five titles in the Expert Review series and seven Future Medicine publications had increased Impact Factors. In addition, Expert Review of Anti-infective Therapy was awarded its first Impact Factor of 2.857 – an exciting development in light of the vast amount of research literature published each year.
Dr David Hughes, Publisher for the Future science Group, said,
“The Future Science Group portfolio brings a new and fresh approach to learned publishing, often addressing areas of science and medicine that are, as yet, in their infancy. It is very exciting, therefore, to see these titles becoming so well established in the journals firmament.”
The Future Science Group has an expanding portfolio of innovative titles, with 2010 launches including Therapeutic Delivery, Pain Management, Diabetes Management, Neurodegenerative Disease Management, Neuropsychiatry and Carbon Management. Full information on all titles can be found at www.expert-reviews.com, www.futuremedicine.com and www.future-science.com. Free institutional site license and personal online trials are available upon request.
-- ENDS --
For further information please contact:
Craig Canham, Corporate Public Relations, Future Science Group
T: +44 (0) 20 8371 6092 F: +44 (0) 20 8371 6099 E: c.canham@futuremedicine.com
Link to this page from
Twitter DeliciousDiggRedditLinkedIn